CareDx (NASDAQ: CDNA) counsel's 2,688-share sale under 10b5-1

Rhea-AI Filing Summary

CareDx, Inc. reported that its Secretary and General Counsel, Jeffrey Adam Novack, executed an open-market sale of 2,688 shares of common stock on May 5, 2026 at a weighted average price of 20.6775 per share. After the sale, he directly owned 113,924 shares of CareDx common stock. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan, which had been adopted on September 4, 2025, and the sale prices ranged from 20.405 to 21.26 per share.

Insider Trade Summary

Net Seller: 2,688 shares ($55,581)

Net Sell 1 txn

Insider Novack Jeffrey Adam

Role Secretary and General Counsel

Sold 2,688 shs ($56K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,688	$20.6775	$56K

Holdings After Transaction: Common Stock — 113,924 shares (Direct, null)

Footnotes (1)

1. The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on September 4, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.405 to $21.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 2,688 shares Weighted average sale price: 20.6775 per share Price range of sales: 20.405 to 21.26 per share +2 more

5 metrics

Shares sold 2,688 shares Open-market sale of common stock on May 5, 2026

Weighted average sale price 20.6775 per share Average price for 2,688 shares sold on May 5, 2026

Price range of sales 20.405 to 21.26 per share Multiple transactions making up the reported sale

Shares owned after transaction 113,924 shares Direct ownership by Jeffrey Novack following the sale

10b5-1 plan adoption date September 4, 2025 Date Novack adopted Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on September 4, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Novack Jeffrey Adam

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD, 4TH FLOOR

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Secretary and General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		S(1)		2,688	D	$20.6775(2)	113,924	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on September 4, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.405 to $21.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Jeffrey Adam Novack	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CareDx (CDNA) report for Jeffrey Novack?

CareDx reported an open-market sale by Jeffrey Novack of 2,688 common shares. The Secretary and General Counsel sold the shares at a weighted average price of 20.6775 per share and held 113,924 shares directly after the transaction, according to the Form 4 filing.

At what price did the CareDx (CDNA) insider sale occur?

The 2,688 CareDx shares were sold at a weighted average price of 20.6775 per share. The filing notes that the trades occurred in multiple transactions, with prices ranging between 20.405 and 21.26 per share, all on May 5, 2026.

How many CareDx (CDNA) shares does Jeffrey Novack own after this Form 4 sale?

After the reported sale, Jeffrey Novack directly owned 113,924 CareDx common shares. This post-transaction holding reflects his remaining position as disclosed in the Form 4, following the open-market sale of 2,688 shares on May 5, 2026.

Was the CareDx (CDNA) insider sale by Jeffrey Novack under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 trading plan. The plan was adopted on September 4, 2025, indicating the May 5, 2026 sale was pre-arranged rather than a discretionary same-day trading decision.

What does the weighted average price mean in the CareDx (CDNA) insider filing?

The weighted average price of 20.6775 per share reflects multiple trades within a price range. According to the Form 4 footnote, the 2,688 shares were sold between 20.405 and 21.26 per share, and the insider can provide detailed breakdowns on request.